Hostname: page-component-5c6d5d7d68-thh2z Total loading time: 0 Render date: 2024-08-19T22:07:51.588Z Has data issue: false hasContentIssue false
  • English
  • Français

In Vitro Activity of Cefixime and Six Other Agents Against Nosocomial Pathogens of the Enterobacteriaceae Family

Published online by Cambridge University Press:  02 January 2015

Maury E. Mulligan  and
Y.Y. Kwok
Maury E. Mulligan*
Affiliation:
Medical and Research Services, Veterans Administration, West Los Angeles Medical Center, and the Department of Medicine, UCLA School of Medicine, Los Angeles, California
Y.Y. Kwok
Affiliation:
Medical and Research Services, Veterans Administration, West Los Angeles Medical Center, and the Department of Medicine, UCLA School of Medicine, Los Angeles, California
*
691/W111F, West Los Angeles Veterans Administration, Wilshire & Sawtelle Blvds., Los Angeles, CA 90073
Get access Rights & Permissions [Opens in a new window]

Abstract

Cefixime, a broad-spectrum, orally active cephalosporin, was more active in vitro than ampicillin, cefaclor, cephalothin, and trimethoprim/sulfamethoxazole against 194 nosocomial pathogens of the family Enterobacteriaceae. Activity was especially good against Klebsiella spp, Proteus spp, Serratia spp, and Providencia stuartii. Although gentamicin had equivalent or better activity against Citrobacter spp, Enterobacter spp, Escherichia coli, and Morganella morganii, all 23 of the gentamicin-resistant strains studied were susceptible to Cefixime. Isolates tested were from urinary tract infections, abdominal infections, wounds, vascular infections, and respiratory infections; they were sequentially collected nosocomial pathogens from a single institution. This orally active cephalosporin should be considered for therapy of a variety of nosocomial infections involving gram-negative bacillary pathogens.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 8 , Issue 6 , June 1987 , pp. 241 - 244
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Neu, HC, Chin, NX, Labthavikul, P: Comparative in vitro activity and B-lactamase stability of FR 17027, a new orally active cephalosporin. Antimkrob Agents Chemother 1984; 26:174–180.Google Scholar
2.Brittain, DC, Scully, BE, Hirose, T, et al: The pharmacokinetic and bactericidal characteristics of oral Cefixime. Clin Pharmacol Ther 1985; 38:590–594.Google Scholar
3.National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Tentative standard M7-T. Villanova, PA, National Committee tor Clinical Laboratory Standards. 1983.Google Scholar
4.Steers, E, Foltz, EL, Graves, BS, et al: An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibiot Chemother 1959; 9:307–311.Google Scholar
5.Kamimura, T, Kojo, H, Matsumoto, Y, et al: In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimkrob Agents Chemother 1984; 25:98–104.Google Scholar
6.Fuchs, PC, Jones, RN, Barry, AL, et al: In vitro evaluation of Cefixime (FK027, FR17027, CL284635): Spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria. Diagn Microbiol Infect Dis 1986; 5:151–162.Google Scholar
7.Kamidono, S, Arakawa, S, Kataoka, N, et al: In vitro and clinical evaluation of FK027 for the treatment of urinary tract infections. Abstract WS-17-9, 14th International Congress of Chemotherapy, Kyoto, Japan, 1985.Google Scholar
8.Kishi, H, Kitahara, K, Tominaga, T, et al: Experimental and clinical evaluation of FK027 activity in the treatment of urinary tract infections. Abstract S-19-7. 14th International Congress of Chemotherapy, Kyoto, Japan, 1985.Google Scholar
9.Ohi, Y, Shimada, T, Kawahara, M, et al: Clinical evaluation of FK027 in urinary tract infections. Abstract S-19-9. 14th International Congress of Chemotherapy, Kyoto, Japan, 1985.Google Scholar
10.Suzuki, K, Tamai, H, Naide, Y, et al: Clinical usefulness of FK027, a new oral cephalosporin, in the treatment of urinary tract infections. Abstract S-19-8. 14th International Congress of Chemotherapy, Kyoto, Japan, 1985.Google Scholar
11.Konishi, K, Tamura, M: Clinical studies of F:K027, a new oral cephalosporin in respiratory tract infections, and its pharmacokinetics. Abstract S-19-5, 14th International Congress of Chemotherapy, Kyoto, Japan, 1985.Google Scholar